Omeprazole vs Pantoprazole: Comparing PPIs in Australia

Proton pump inhibitors (PPIs) are among the most widely prescribed medications in Australia. According to PBS dispensing data, PPI prescriptions consistently rank among the top 10 most dispensed medication classes nationally. Omeprazole and pantoprazole are the two most common, and GPs are frequently asked which is "better." The short answer: they are very similar in effectiveness, but differ in drug interactions, formulation, and a clinically important scenario involving antiplatelet therapy.

PPIs irreversibly block the hydrogen-potassium ATPase enzyme (the proton pump) in the stomach lining's parietal cells. This is the final common pathway of acid secretion. By blocking this pump, PPIs reduce stomach acid production by approximately 90% at full therapeutic doses. All PPIs work by the same mechanism -- the differences are pharmacokinetic (how the body processes them), not pharmacodynamic (what they do to the proton pump).

Both omeprazole and pantoprazole are prodrugs that require acid activation in the canalicular space of parietal cells before they can bind irreversibly to the proton pump. This is why they are most effective when taken before a meal.

Omeprazole was the first PPI to receive TGA registration in Australia (1988). It remains one of the most prescribed medications in the country.

The clopidogrel interaction is the most important clinical concern with omeprazole (see section below).

Pantoprazole gained clinical prominence partly because of its cleaner interaction profile with other medications.

The key pharmacological distinction is that pantoprazole has weaker competitive inhibition of CYP2C19, meaning it is less likely to interfere with medications that depend on this enzyme for activation.

For the most common indications -- gastro-oesophageal reflux disease (GORD), peptic ulcer disease, and H. pylori eradication (combined with antibiotics) -- multiple meta-analyses show no clinically significant difference in effectiveness between omeprazole and pantoprazole at equivalent doses. Oesophagitis healing rates and symptom relief for reflux are essentially identical.

This is the most clinically important difference between the two PPIs in current Australian practice.

Clopidogrel (a common antiplatelet medication used after myocardial infarction, coronary stent placement, and ischaemic stroke) is a prodrug requiring activation by the CYP2C19 enzyme -- the same enzyme that metabolises omeprazole. Concurrent omeprazole use can meaningfully reduce clopidogrel's antiplatelet effect by competing for CYP2C19, potentially increasing cardiovascular risk in patients who depend on antiplatelet therapy.

The Australian Therapeutic Guidelines (eTG Complete, Gastrointestinal section) specifically recommend pantoprazole or rabeprazole over omeprazole for patients taking concurrent antiplatelet therapy, particularly clopidogrel. This recommendation is also reflected in cardiology prescribing guidance from the National Heart Foundation.

Side-effect profiles are very similar between the two PPIs. Most are class effects (shared by all PPIs) rather than drug-specific.

Common side effects (1-10% of patients):

Red flags

View larger image

Trouble swallowing, bleeding, weight loss, persistent vomiting, chest pain, or anaemia need medical assessment.

• Headache
• Nausea, diarrhoea, constipation, or abdominal discomfort
• Flatulence

Long-term use considerations (beyond 6-12 months):

• Vitamin B12 deficiency: reduced gastric acid impairs B12 absorption from food. Australian guidelines recommend B12 monitoring after 2 or more years of PPI use. Symptoms may be subtle (fatigue, peripheral neuropathy).
• Magnesium deficiency: uncommon but clinically significant with prolonged use (beyond 1 year at therapeutic doses). Symptoms include muscle cramps, tremor, and cardiac arrhythmias. Serum magnesium should be checked in at-risk patients.
• Fracture risk: observational studies have raised the possibility that long-term PPIs reduce calcium absorption and increase fracture risk, though the evidence is mixed and effect sizes are small. The eTG notes this as a consideration for patients on long-term therapy.
• Clostridioides difficile infection: reduced stomach acid may increase susceptibility to C. difficile. This risk is most relevant in hospitalised or elderly patients, or those taking antibiotics concurrently.
• Rebound acid hypersecretion: stopping PPIs abruptly after prolonged use can cause temporary worsening of reflux symptoms due to rebound acid overproduction. The eTG recommends gradual dose tapering when discontinuing long-term PPI use.

Both omeprazole and pantoprazole are PBS-listed for the following indications: GORD (documented oesophagitis), peptic ulcer disease (including H. pylori eradication), and prevention of NSAID-associated ulcers in high-risk patients.

Low-dose omeprazole and pantoprazole are also available over the counter as Pharmacy Medicines for short-term reflux. Generic omeprazole and pantoprazole are bioequivalent to the branded versions (Losec, Somac) under TGA requirements. Your pharmacist can confirm the price of the exact item dispensed.

PPIs are highly effective but are commonly continued longer than clinically necessary. The eTG recommends using the lowest effective dose for the shortest appropriate duration, with regular clinical review. Patients with gastritis or H. pylori-associated ulcers should have a defined treatment endpoint rather than ongoing open-ended PPI use.

Long-term PPI use is appropriate for:

• Barrett's oesophagus (ongoing acid suppression is recommended to reduce adenocarcinoma risk)
• Severe erosive oesophagitis that relapses on stepping down
• Concurrent NSAID use in patients with multiple high GI bleeding risk factors
• Zollinger-Ellison syndrome

Stepping down or stopping when:

• GORD symptoms are controlled and no high-risk features are present
• The original indication has resolved (e.g., H. pylori eradicated, NSAID course completed)
• The patient can manage symptoms with lifestyle modification alone

Lifestyle modifications that reduce PPI dependence include: elevating the head of the bed (raising the bed frame, not just using extra pillows), avoiding eating within 2-3 hours of lying down, limiting caffeine, alcohol, and fatty foods if they trigger symptoms, achieving a healthy body weight (excess abdominal adiposity increases intra-abdominal pressure), and smoking cessation.

Low-dose omeprazole (10-20mg) and pantoprazole (20mg) are available without a prescription from pharmacies as Schedule 3 medicines. Higher doses and PBS-subsidised supply require a doctor's prescription. For ongoing repeat prescriptions of an established PPI for a stable, well-documented condition, telehealth is a convenient option -- a doctor can review your history and issue an eScript sent directly to your phone.

• Healthdirect: Gastro-oesophageal reflux disease (GORD)
• Australian Prescriber: proton pump inhibitors
• Gastroenterological Society of Australia (GESA)
• Australian Commission on Safety and Quality in Health Care
• TGA: Poisons Standard and medicine scheduling